"Gilead's Stock Plummets on Disappointing Lung Cancer Drug Trial Results"

Gilead's stock dropped over 10% after disappointing results from a late-stage trial showed that its drug, Trodelvy, did not significantly extend the lives of patients with a certain type of lung cancer. Despite the drug already being approved for some types of breast and bladder cancers, the phase-three study aimed to expand its use. Gilead will discuss the results with regulators to determine if certain lung cancer patients may still benefit from the drug, which belongs to the sought-after class of antibody-drug conjugates. Analysts suggest that the trial results could impact investor confidence in Gilead's potential sales in oncology.